Identification of mouse helper epitopes for WT1-specific CD4+ T cells

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2021-07-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-021-03003-5PMID 34272593PMCID PMC10992340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

  2020cited by this paper
• T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

  2019cited by this paper
• Phase I/II Pilot Study of Wilms' Tumor 1 Peptide‐Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer

  2019cited by this paper
• Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

  2018cited by this paper
• WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies

  2018cited by this paper
• WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.

  2018cited by this paper
• A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

  2018cited by this paper
• Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse

  2018cited by this paper
• CD4+ T cell help in cancer immunology and immunotherapy

  2018cited by this paper
• Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides

  2018cited by this paper
• Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

  2018cited by this paper
• Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy

  2017cited by this paper
• Vaccines targeting helper T cells for cancer immunotherapy.

  2017cited by this paper
• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

  2016cited by this paper
• Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

  2015cited by this paper
• Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.

  2015cited by this paper
• CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful

  2014cited by this paper
• Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

  2014cited by this paper
• WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

  2013cited by this paper
• WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission

  2012cited by this paper
• Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma.

  2012cited by this paper
• Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.

  2012cited by this paper
• Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

  2011cited by this paper
• WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.

  2010cited by this paper
• WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient

  2010cited by this paper
• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  2009cited by this paper
• A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

  2009cited by this paper
• Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.

  2009cited by this paper
• CD4 T cells: fates, functions, and faults.

  2008cited by this paper
• Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

  2008cited by this paper
• WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma

  2007cited by this paper
• A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.

  2006cited by this paper
• Wilms’ tumor gene WT1 17AA(–)/KTS(–) isoform induces morphological changes and promotes cell migration and invasion in vitro

  2006cited by this paper
• Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway

  2006cited by this paper
• WT1 Peptide‐Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases

  2004cited by this paper
• MHC ligands and peptide motifs: first listing

  2004cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application

  2001cited by this paper
• Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product1

  2000cited by this paper
• SYFPEITHI: database for MHC ligands and peptide motifs

  1999cited by this paper

• Development of a multi-neoepitope vaccine targeting non-small cell lung cancer through reverse vaccinology and bioinformatics approaches

  2025cites this paper
• Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine

  2025cites this paper
• Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report

  2024cites this paper
• Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia

  2023cites this paper
• Wilms’ tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives

  2023cites this paper